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a  b  s  t  r  a  c  t
There  is  increasing  use  of  circulating  cell  death  biomarkers  in  patients  and  clinical  trials.  Knowledge  of  the
potential  noise  and confounders  in assays  are vital  for biomarker  interpretation.  The  daily  and  diurnal
variability  and  effect  of  menstruation  and  exercise  on  nucleosomal  DNA  (nDNA),  total  cytokeratin  18
(tK18)  and  apoptotic  speciﬁc  cytokeratin  18 (cK18)  were  assessed  in  3  cohorts  of healthy  volunteers;  12
pre-menopausal  women  to  establish  the  effect  of  menstruation,  12  men  to  perform  exercise  and  12 post-
menopausal  women.  All 36 subjects  were evaluated  to  establish  daily  and diurnal  variability.  Estimates  of
variability  were  derived  in  a linear  mixed  effects  model  and presented  as the  back  transformed  coefﬁcient
of  variation  (%CV).iomarker
xercise
enstruation
Minimal  variation  was  seen  in  cK18  (11%CV)  and  tK18  (11%CV)  but higher  variability  was  seen in
nDNA  (85%CV).  K18 results  appeared  stable  throughout  the  day but  a possible  peak  in nDNA  was  seen
at  15:00.  Menstruation  had  minimal  effects  but  exercise  led  to immediate  short-lived  elevations  in  cell
death biomarkers.
There  is  no evidence  of  signiﬁcant  daily variability  in  K18  assays.  We  recommend  subjects  should  not
exercise  for  6 h  before  blood  sampling.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction
There is increasing evidence of the utility of circulating cell
eath biomarkers in oncology, immunology, toxicology, sepsis, car-
iology and hepatology [1–4]. Recent research has focussed on
easurement of circulating nucleosomal DNA (nDNA) and cyto-
eratin (K) 18 fragments [5–7].
During apoptosis DNA is cleaved into nucleosomes, and
ecrosis also results in elevated nDNA due to secondary apo-
tosis of macrophages [8]. Circulating nDNA levels are higher in
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Open access under CC BY-NC-Nauto-immune disease and cancer suggesting increased production,
decreased clearance or both [4].
Cytokeratins are components of the epithelial cytoskeleton that
are cleaved during apoptosis. The M30  ELISA detects an apoptotic
speciﬁc K18 neo-epitope (cK18) whilst a companion ELISA (M65)
detects total soluble K18 (tK18); including apoptotic fragments and
full-length K18 released during necrosis [7].
Knowledge of the assay ‘noise’ (the technical variation, biolog-
ical variability and potential confounders) is vital in biomarker
interpretation [9,10]. The use of cell death biomarkers without this
knowledge could lead to potentially misleading results, severely
limiting the utility of these promising assays for clinical deci-
sion making. As cell death biomarkers change rapidly following
some types of therapy [11,12], it is important to distinguish drug
induced change from day to day (daily) and hour to hour (diur-
nal) variation. Exercise and menstruation could also potentially
affect apoptotic biomarkers [13–15]. Therefore this study set out
to determine the diurnal and daily variation and the effects of
the menstruation or exercise on serum cK18, tK18 and nDNA in
healthy subjects, to help assess their suitability for routine clinical
use.
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The primary objective was  to estimate variability components
within and between subjects and days. The main source of vari-
ability in cK18 and tK18 levels was accounted for by differences
Table 1
Demographics of subjects (age and body mass index (BMI) expressed as median
with range in brackets).
Age BMI RaceA. Greystoke et al. / Journal of Pharmaceut
. Materials and methods
Three cohorts of healthy volunteers were enrolled; 12 pre-
enopausal women to establish the effect of menstruation, 12
ost-menopausal women to act as controls for this analysis and
2 men  to establish the effect of moderate exercise. All 36 subjects
ere evaluated to establish daily and diurnal variability.
.1. Study inclusion and exclusion criteria
Subjects were selected from the AstraZeneca Healthy Volun-
eer Panel. Obese subjects (BMI > 32 for women; >35 for men),
ubjects with cancer, auto-immune disease, hepatitis and human
mmunodeﬁciency virus were excluded due to elevated cell death
iomarkers in these conditions [3,4,6]. Women  taking hormone
eplacement therapy were also excluded. Male subjects were
xcluded if considered by the screening physician to be unable to
erform a period of moderate physical exercise. Menopausal status
as checked in the post menopausal women by assessment of FSH,
H, oestradiol and progesterone at screening.
.2. Conduct of study
The protocol received approval from Yorkshire Independent
esearch Ethics Committee. Following written informed consent
ubjects spent two 24 h periods 4 weeks apart at the Clinical Phar-
acology Unit (CPU) at AstraZeneca, Alderley Edge where serum
as collected every 6 h starting at 9 AM to give broad coverage
hroughout a 24 h period, whilst minimising blood draws. All sub-
ects attended the CPU twice weekly during the 4 weeks to establish
he daily variation, and to assess changes in the pre-menopausal
omen during the follicular and luteal phases of the menstrual
ycle. In addition, during both residential stays, men  performed a
eriod of exercise consisting of cycling between 60 and 70 rev-
lutions per minute (rpm) on an ergometer (ERG 911 S) starting
t 25 W.  Every 3 min  the resistance was increased by 25 W.  The
xercise ended if the subject became distressed, failed to main-
ain 60 rpm for 20 s or heart rate exceeded 85% of age predicted
aximum rate (226-subject age beats per minute). Additional
lood samples were taken immediately before and after exer-
ise.
Pre-menopausal women  donated samples daily during men-
truation. Menstruation is the time where maximal apoptosis is
een in the breast and uterus, so any effect on cell death biomark-
rs should be most obvious. Menstruation also acted as a cue for
ubjects to attend for sampling at a time when their reproductive
ycles were approximately synchronised. This was  conﬁrmed by
ssessment of FSH, LH, oestradiol and progesterone at all sampling
ime-points.
.3. Assays
Blood was collected in tubes containing a silica clot activator and
entrifuged at 2000 g for 10 min  to obtain serum. The sample collec-
ion, processing and storage were as previously described [1]. The
30  and M65  ELISAs are commercially available assays operated
ccording to the manufacturer’s instructions (Peviva, Sweden). In
rief 25 L of sample is analysed in a sandwich ELISA based around
 mouse monoclonal antibody to K18 and a horseradish peroxidase
HRP) conjugated secondary antibody (either the M30  antibody
gainst K18asp396 neo-epitope (cK18) or a second monoclonal
ntibody to K18 (tK18)). A 7 step calibration curve was generated
sing a recombinant protein fragment and results expressed as U/L.
hanges in levels were expressed as the % change compared to
aseline as in the previous literature [1,2].d Biomedical Analysis 84 (2013) 184– 188 185
nDNA was assessed using the Cell Death Detection ELISAplus
(Roche, Switzerland) according to manufacturer’s instructions. In
brief 20 L of sample is analysed in a sandwich ELISA based around
an anti-histone antibody conjugated to biotin and an anti-DNA anti-
body conjugated to HRP, captured on a streptavidin coated plate.
Results are reported as optical density measured at 405 nm using
Revelation Software on a Dynex MRXII plate reader. Changes in lev-
els were expressed as absolute change in optical density as in the
previous literature [1,5]. Full blood count, urea and electrolytes and
liver function tests were assessed at all time-points using routine
methods by the Safety Assessment Department at AstraZenenca,
Macclesﬁeld, UK.
2.4. Statistical considerations
The objectives were to derive estimates of variability; therefore
no formal power calculations were done. However, cohorts of 12
subjects were considered sufﬁcient for judgements on biomarker
variability [16]. Similar numbers were used to judge the noise
of these biomarkers in patients with cancer [9]. Variables were
log-normally distributed and so were logarithmically transformed.
In order to derive estimates of the variability between subjects
and from hour to hour and day to day within a subject a linear
mixed effects model with random effects for subject and ﬁxed
effects for time and day was constructed. The impact of men-
struation and exercise was  assessed by secondary models with
that parameter as a ﬁxed effect. The estimated impact of poten-
tial confounding factors on the biomarkers is presented as the
possible percentage change in the assay (the back transformed
coefﬁcient of variation derived in the model with 95% conﬁdence
intervals).
3. Results
The demographics of the subjects are shown in Table 1. Two
subjects had no evaluable results due to new diagnoses of hyper-
tension (male) and breast cancer (post-menopausal female) during
the study.
3.1. Levels of circulating cell death biomarkers in subjects.
Levels of cK18 (median 106 U/L (range 74–1000 U/L; inter-
quartile range (IQR) 92–139 U/L)) and tK18 (median 281 U/L (range
68–1247 U/L; IQR 229–346 U/L)) were similar to those reported
in the literature (Supplemental Tables S1, S2). As nDNA is a
quasi-quantitative assay [10], it is difﬁcult to compare results
across laboratories; however, results were similar to our previ-
ous publications with a median of 0.2 (range 0–1.9 (IQR 0.2–0.6))
[1,2].
3.2. Day to day variabilityMale 49.5 (34–60) 26.3 (21.4–29.7) 12 Caucasian (100%)
Female
Post-menopausal 60.5 (45–69) 26.5 (21.2–29.3) 12 Caucasian (100%)
Pre-menopausal 44.5 (25–50) 26.3 (20.8–29.4) 12 Caucasian (100%)
186 A. Greystoke et al. / Journal of Pharmaceutical and Biomedical Analysis 84 (2013) 184– 188
cK18
tK18
M
e
a
n
 K
1
8
 A
n
ti
g
e
n
 U
/L
100
200
300
400
0.1
0.3
1
M
e
a
n
 n
D
N
A
 (
O
D
)
B)
A)
nDNA
Fig. 1. Variation in (A) cleaved and total K18 (cK18 and tK18) in healthy subjects
and  (B) nucleosomal DNA (nDNA) in healthy female subjects over 28 days (values
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Fig. 2. Box and Whisker plot of changes in cell death biomarkers during the 1st 5
days of menstruation in healthy female subjects. (A) Changes in cleaved cytokeratin
18 (cK18) and total K18 (tK18) expressed as % change in levels compared to the
study was  relatively small (36 subjects screened); the extensivexpressed as mean ± standard error of the mean; shaded areas represent 24 h stays
n  the Clinical Pharmacology Unit at AstraZeneca).
etween the subjects (59% and 27%, respectively). There was min-
mal within-subject daily variability in both cK18 and tK18 (6%
nd 7%, respectively). A higher within-subject daily variability
f 40% was seen in nDNA, closer to the inter-subject variability
f 58%.
.3. Hour to hour variability
Diurnal variability within the subjects was similar to daily vari-
bility (11% for cK18, 11% for tK18 and 85% for nDNA). There was
o apparent time of day associated with any consistent change in
18 assays (Fig. 1A) or in nDNA when all subjects were assessed
ogether. However, since men  exercised during these periods and
his could obscure any diurnal variability, the analysis was repeated
ith the men  excluded. Again no differences in cK18 and tK18 were
ound, however higher nDNA was apparently seen in women  at
5:00 compared to 9:00 during both periods (Fig. 1B) (mean change
eek 1 + 0.19 (range −0.62 to 1.64; p = 0.04); mean change week
 + 0.22 (range −0.21 to + 1.98; p = 0.02).
.4. Effect of menstruation
There was some evidence of a decrease in cK18 during menstru-
tion (mean change −7% (95%CI −11% to −4%) although this may
ot to be clinically meaningful as it is close to the daily variability.
here was no obvious effect of menstruation on tK18 (mean change
% (95%CI −4% to 5%)); and nDNA (mean change18% (95%CI −39%
o 11%))(Fig. 2).mean value for each individual when not menstruating; (B) changes in nucleosomal
DNA (nDNA) expressed as absolute change in optical density compared to the mean
value for each individual when not menstruating).
3.5. Effect of exercise
The period of exercise (median 16 (range 10–25) min) did
not cause any signiﬁcant creatine kinase rise in the follow-
ing 12 h (pre-exercise 176 ± 30 IU/L, 6 h later 193 ± 70 U/L, 12 h
later 199 ± 89 U/L). However, immediately post exercise signiﬁcant
increases in cK18 (mean change +8% (95% CI 0.3–16.4%; range –14%
to 38%; p = 0.006) and nDNA (mean change +0.20 (95%CI 0.05–0.42;
range −1.27 to 1.24; p = 0.0004)) and a non-signiﬁcant increase in
tK18 (mean change +2% (95% CI −3.6% to 8.8%; range −10% to 20%;
p = 0.19) were seen (Fig. 3). There was  no relationship between the
length of exercise and rise in cK18 and nDNA (R = −0.33 and 0.28,
respectively; NS). The elevations in cell death biomarkers were
short-lived, and resolving by the time of the next blood sample
(Fig. 3).
4. Discussion
The potential utility of these biomarkers has been recently
reported [1–7] and this is anticipated to lead to greater use in both
research and clinical practice. Before they can be used in clinical
decision making it is necessary to determine potential variabil-
ity and confounding factors. Whilst the number of subjects in thissampling performed (with up to 17 samples per subject and 522
samples analysed) and the duplication of the 24 h stays in all sub-
jects allowed us to draw meaningful conclusions.
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Fig. 3. Box and Whisker plot of changes in cell death biomarkers following exercise
in  healthy male subjects. Samples taken immediately post exercise and at 15:00
(median 3.4 (range 1.2–5.2) h post exercise). (A) Changes in cleaved cytokeratin 18
(cK18) and total K18 (tK18) expressed as % change in levels compared to the value
immediately prior to exercise; (B) changes in nucleosomal DNA (nDNA) expressed
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[14] G.G. Bon, P. Kenemans, J.J. Dekker, P.G. Hompes, R.A. Verstraeten, G.J. van Kamp,
J.  Schoemaker, Fluctuations in CA 125 and CA 15-3 serum concentrations durings  absolute change in optical density compared to the value immediately prior to
xercise).
The variability for cK18 and tK18 within subjects (8–11%) are
imilar to the reported technical variability for the assays and less
han that reported for repeated measures in cancer patients [9],
uggesting that there is minimal biological variation in this setting.
he higher variability observed in nDNA suggests that its use in
ealthy subjects without other corroborating cell death biomarkers
ay be restricted. This study was performed in healthy subjects
here levels of circulating nDNA are low [4], lower than in patients
ith cancer and in the bottom 10% of the assay’s dynamic range.
he daily and diurnal variability in patients where baseline levels
re higher may  be less problematic.
No diurnal variation was seen in the K18 assays, however in
omen elevated nDNA levels could be seen at 15:00 h. This could
ot be conﬁrmed in male subjects due to overlapping effects of
xercise on nDNA. The reason for this ﬁnding is unclear. This peak
f nDNA in the early afternoon does not correlate with the diurnal
ariation of physiological hormones.
There was no major effect of menstruation; the slight decrease
n cK18 was not associated with concurrent changes in tK18 and
DNA and was  close to the daily variability of this biomarker. This
ack of effect of menstruation on nDNA was unexpected given the
ajor changes in proliferation and apoptosis in the breast and
terus observed throughout the menstrual cycle [15]. Whilst there
s no expression of K18 in the uterus, it is found within the breast
17]. This might suggest that products from the cells dying dur-
ng menstruation have limited access to circulation and are either
hagocytosed or shed in the menses.
[d Biomedical Analysis 84 (2013) 184– 188 187
The period of exercise did not cause any signiﬁcant myocyte
damage. However, immediately post exercise short-lived increases
in cK18 and nDNA were seen. Consideration of these potential
changes may  be particularly important with therapies where
a rapid change in cell death biomarkers is anticipated [11,12].
Strenuous exercise results in the generation of free radicals, inﬂam-
mation and apoptosis [18]. However, the time-scale of this process
(several hours post exercise) does not match the observed kinetics
of changes in cell death biomarkers [19,20]. During exercise cardiac
output is re-distributed with increased ﬂow through muscles and
decreased ﬂow to viscera. The mechanism of clearance of K18
and nDNA remain unclear, but possibly changes in cardiac output
could lead to decreased clearance and raised levels.
5. Conclusions
We have demonstrated minimal biological variability in K18
assays; further conﬁrming the robustness of these assays. We  rec-
ommend subjects should not exercise for 6 h before blood sampling.
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